Clinical Research Studies for
Pediatric Migraine

Frequently Asked Questions (FAQS)

Open All
Close All
This research study is evaluating a study treatment for migraines in children and teens with recurrent migraines. Your child may be able to take part in this study if they:
  • Are 6 to 17 years old
  • Have between 2 and 8 moderate to severe migraine attacks per month
  • Have parental consent to participate

Participation includes up to 4 study visits over the course of up to 18 weeks. If your child qualifies, they will be randomly assigned to either the study treatment or a placebo (a substance that looks like the study treatment but has no active ingredients). Neither your child nor the study staff will know your child’s assignment. Those who receive placebo may have the option to receive the study treatment at a later time. The study treatment will be dispensed at the study center by study staff. Participants will log their migraines and outcomes in an electronic study diary.

If eligible, participation can last about 18 weeks, which includes 4 visits to the study center.

The study treatment is an oral tablet.

Do not discontinue any medication unless you are advised to do so by the study center staff or your child’s primary care provider.

There is no cost to you for participating in the study.

Clinical research studies are designed in specific ways, and one or more of the answers that you provided were outside of the guidelines for this study. This does not mean your child will not qualify for different research studies.

Open All
Close All

This research study is evaluating a study treatment for migraines in children and teens. Your child may be able to take part in this study if they:

  • Are 6 to 17 years old
  • Have 4 to 14 migraine headache days with at least 2 migraine attacks per month
  • Have had migraines for at least 6 months prior to the initial study visit

Participation includes up to 18 study visits over the course of up to 18 months. If your child qualifies, they will be randomly assigned to either the study treatment or a placebo (a substance that looks like the study treatment but has no active ingredients). Neither your child nor the study staff will know your child’s assignment. Those who receive placebo may have the option to receive the study treatment at a later time. The study treatment will be dispensed at the study center by study staff. Participants will log their migraines and outcomes in an electronic study diary.

If eligible, participation can last about 18 months, which includes 18 visits to the study center.

The study treatment is a liquid solution contained in a prefilled syringe that will be delivered via subcutaneous injection (under the skin).

Do not discontinue any medication unless you are advised to do so by the study center staff or your child’s primary care provider.

There is no cost to you for participating in the study.

Clinical research studies are designed in specific ways, and one or more of the answers that you provided were outside of the guidelines for this study. This does not mean your child will not qualify for different research studies.

Open All
Close All

This research study is evaluating a study treatment for migraines in teens. Your child may be able to take part in this study if they:

  • Are 12 to 17 years old
  • Have headaches 15 or more days per month, with migraine symptoms at least 8 days per month
  • Have had migraines for at least 3 months

Participation includes up to 18 study visits over the course of up to 18 months. If your child qualifies, they will be randomly assigned to either the study treatment or a placebo (a substance that looks like the study treatment but has no active ingredients). Neither your child nor the study staff will know your child’s assignment. Those who receive placebo may have the option to receive the study treatment at a later time. The study treatment will be dispensed at the study center by study staff. Participants will log their migraines and outcomes in an electronic study diary.

If eligible, participation can last about 18 months, which includes 18 visits to the study center.

The study treatment is a liquid solution contained in a prefilled syringe that will be delivered via subcutaneous injection (under the skin).

Do not discontinue any medication unless you are advised to do so by the study center staff or your child’s primary care provider.

There is no cost to you for participating in the study.

Clinical research studies are designed in specific ways, and one or more of the answers that you provided were outside of the guidelines for this study. This does not mean your child will not qualify for different research studies.

Your choice regarding cookies on this site -

We use cookies to optimize site functionality and give you the best experience. Necessary cookies enable core functionality. The website cannot function properly without these cookies and can only be disabled by changing your browser preferences.

For more detailed information on the cookies we use, please check our Privacy Policy.

By continuing to access this website, you are giving us consent to collect cookies.